论文部分内容阅读
抗胸腺细胞球蛋白(ATG)联合环孢霉素A(CSA)为目前严重型再生障碍性贫血(SAA)首选治疗措施之一,本前瞻性随机研究目的在于评价CSA单用治疗非严重型再生障碍性贫血(NSAA)的疗效与ATG联合CSA方案有无可比性。 115例初治的NSAA(中性粒细胞绝对值ANC≥0.5×10~9/L,输血依赖)随机分成CSA组与ATG+CSA组,CSA 5mg/kg.d,+1～+180天,待外周血细胞水平达平台期后CSA剂量逐渐减低;ATG15mg/kg·d,+1～+5天。6个月时判断疗效。
Anti-thymocyte globulin (ATG) combined with cyclosporin A (CSA) is currently the first choice of treatment for severe aplastic anemia (SAA). The purpose of this prospective randomized study was to evaluate the efficacy of CSA alone in the treatment of non-severe Is there any difference between the curative effect of obstacle anemia (NSAA) and the combination of ATG and CSA? One hundred and fifteen patients with newly diagnosed NSAA (absolute neutrophil ANC≥0.5 × 10 ~ 9 / L, transfusion dependent) were randomly divided into CSA group and ATG + CSA group, CSA 5mg / kg.d, +1 to + 180 days, When the level of peripheral blood cells reached plateau, the dose of CSA gradually decreased; ATG15mg / kg · d, + 1 ~ + 5 days. 6 months to determine the efficacy.